Afuco™ Anti-Aβ or Abeta ADCC Therapeutic Antibody (AAB-002), ADCC Enhanced
Anti-Aβ or Abeta ADCC Enhanced Antibody (AAB-002) is an ADCC enhanced antibody produced by our Afuco™ platform. Bapineuzumab (AAB-001) that binds to beta amyloid peptide in the brainis is an experimental humanized monoclonal antibody, and it is being studied as a potential treatment for mild to moderate Alzheimer's disease. Bapineuzumab has received fast-track designation from the FDA, which means that it may receive expedited approval in certain circumstances, in recognition of its potential to address the significant unmet needs of patients with Alzheimer's disease.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-749CL |
| Pricing | Inquiry |
| Type | ADCC enhanced antibody |
| Storage | Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°C. |
| Host | Humanized |
| Target | Aβ or Abeta |